Nicox (OTCMKTS:NICXF – Get Free Report) and Janux Therapeutics (NASDAQ:JANX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings and valuation.
Volatility and Risk
Nicox has a beta of -0.04, suggesting that its share price is 104% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.58, suggesting that its share price is 158% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and target prices for Nicox and Janux Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nicox | 0 | 1 | 1 | 0 | 2.50 |
| Janux Therapeutics | 2 | 3 | 9 | 1 | 2.60 |
Insider and Institutional Ownership
75.4% of Janux Therapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Nicox and Janux Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nicox | $3.59 million | 5.76 | -$24.23 million | N/A | N/A |
| Janux Therapeutics | $13.73 million | 64.12 | -$113.62 million | ($1.84) | -7.85 |
Nicox has higher earnings, but lower revenue than Janux Therapeutics.
Profitability
This table compares Nicox and Janux Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nicox | N/A | N/A | N/A |
| Janux Therapeutics | N/A | -12.93% | -12.23% |
Summary
Janux Therapeutics beats Nicox on 9 of the 12 factors compared between the two stocks.
About Nicox
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.
About Janux Therapeutics
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Receive News & Ratings for Nicox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nicox and related companies with MarketBeat.com's FREE daily email newsletter.
